...
首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel Tacrine Derivatives with a Combination of Acetylcholinesterase Inhibition and Cannabinoid CB1 Receptor Antagonism
【24h】

Design, Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel Tacrine Derivatives with a Combination of Acetylcholinesterase Inhibition and Cannabinoid CB1 Receptor Antagonism

机译:设计,合成,生物学特性和分子建模研究新型的他克林衍生物与乙酰胆碱酯酶抑制和大麻素CB1受体拮抗作用相结合。

获取原文
获取原文并翻译 | 示例
           

摘要

Pyrazolines 7-10 were designed as novel CB1 receptor antagonists, which exhibited improved turbidimetric aqueous solubilities. On the basis of their extended CB1 antagonist pharmacophore, hybrid molecules exhibiting cannabinoid CB1 receptor antagonistic as well as acetylcholinesterase (AChE) inhibiting activities were designed. The target compounds 12, 13, 20, and 21 are based on 1 (tacrine) as the AChE inhibitor (AChEI) pharmacophore and two different CB1 antagonistic pharmacophores. The imidazole-based 20 showed high CB1 receptor affinity (48 nM) in combination with high CB1/CB2 receptor subtype selectivity (> 20-fold) and elicited equipotent AChE inhibitory activity as 1. Molecular modeling studies revealed the presence of a binding pocket in the AChE enzyme which nicely accommodates the CB1 pharmacophores of the target compounds 12, 13, 20, and 21.
机译:吡唑啉7-10被设计为新型的CB1受体拮抗剂,具有更好的浊度水溶液溶解度。基于其扩展的CB1拮抗剂药效基团,设计了具有大麻素CB1受体拮抗作用和乙酰胆碱酯酶(AChE)抑制活性的杂合分子。目标化合物12、13、20和21基于1(他克林)作为AChE抑制剂(AChEI)药效团和两种不同的CB1拮抗药效团。基于咪唑的20显示出高的CB1受体亲和力(48 nM)与高的CB1 / CB2受体亚型选择性(> 20倍)结合,并引起了等价的AChE抑制活性,为1。分子模型研究表明,在很好地容纳目标化合物12、13、20和21的CB1药效团的AChE酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号